Last Updated on September 7, 2022 by GlobeNewsWire
CHESTERBROOK, Pa., Sept. 07, 2022 (GLOBE NEWSWIRE) — Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the Company will present a corporate overview at the H.C. Wainwright Annual Global Investment Conference being held in-person and virtually September 12- 14, 2022, in New York.
Presentation DetailsDate: Monday, September 12, 2022Time: 4:30pm ETWebcast Link
A link to the webcast will be available on the Events page of the Investors section of the Company’s website at https://www.trevena.com/investors/events-presentations/ir-calendar
A replay of the presentation will be archived on the website and available for approximately 30 days following the event. Please contact your H.C. Wainwright representative to schedule one-on-one meetings with Trevena during the conference.
Trevena, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines for patients with CNS disorders. The Company has one approved product in the United States, OLINVYK(R) (oliceridine) injection, indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. The Company’s novel pipeline is based on Nobel Prize winning research and includes three differentiated investigational drug candidates: TRV045 for diabetic neuropathic pain and epilepsy, TRV250 for the acute treatment of migraine and TRV734 for maintenance treatment of opioid use disorder.
For more information, please visit www.Trevena.com
For more information, please contact:
Dan FerryManaging DirectorLifeSci Advisors, LLCdaniel@lifesciadvisors.com(617) 430-7576
PR & Media Contact:
Sasha BennettAssociate Vice PresidentClyde GroupSasha.Bennett@clydegroup.com(239) 248-3409
Bob YoderSVP and Chief Business OfficerTrevena, Inc.(610) 354-8840